Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event

    loading  Checking for direct PDF access through Ovid

Abstract

A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with 177Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct.

Related Topics

    loading  Loading Related Articles